methylphenidate prolonged release tablet - 12 hrs acting / Generic mfg. - LARVOL DELTA

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (clinicaltrials.gov) - P2 | N=175 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Sep 2026 ➔ Sep 2028 | Trial primary completion date: Sep 2026 ➔ Sep 2028

Trial completion date • Trial primary completion date • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Updates in treatment strategies in ADHD (WFSBP 2026) - "Lisdexamfetamine, a prodrug cleaved gradually by red blood cell enzymes, provides smoother pharmacokinetics and lower abuse potential due to slower peak concentrations...OROS-methylphenidate mimics twice-daily dosing through osmotic release, while transdermal methylphenidate bypasses first-pass metabolism and reduces appetite suppression. Serdexmethylphenidate and ion-exchange amphetamine preparations further improve duration and plasma stability...These mechanisms may improve emotional dysregulation and provide faster onset than atomoxetine...Investigational therapies include centanafadine, a triple DAT-NET-SERT inhibitor targeting emotional dysregulation; TAAR-1 agonists, which modulate dopamine and glutamate signaling; and metadoxine extended release, which restores GABA-glutamate balance and may preferentially benefit inattentive ADHD...DAT1 and SERT polymorphisms may predict stimulant or serotonergic treatment response, while COMT Val158Met variants influence..."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Psychiatry • Tic Disorders • Tourette Syndrome • COMT

Clearing the Fog - Investigating the Use of Stimulant Therapy in the Treatment of POTS: A Literature Review (APA 2026) - "Conventional therapies (e.g., beta-blockers, ivabradine, midodrine) rarely address these symptoms, prompting some clinicians to trial stimulants off-label...Keywords included "Postural Orthostatic Tachycardia Syndrome", "POTS", "methylphenidate", "Concerta", "modafinil", "amphetamine", and "stimulant." Articles were eligible if they reported clinical outcomes of stimulant therapy in POTS...A pediatric cohort exhibited an overall effectiveness of 68.8%, with methylphenidate effective in 53% and atomoxetine in 16%... Stimulants may represent a valuable adjunct for refractory fatigue and cognitive dysfunction in POTS, particularly among patients with psychiatric comorbidity. Given that these medications are commonly prescribed in psychiatry for attention, mood, and cognitive disorders, clinicians should be aware of POTS to avoid misattributing autonomic dysfunction to primary psychiatric illness. The..."

Review • Cardiovascular • CNS Disorders • Cognitive Disorders • Developmental Disorders • Mental Retardation • Novel Coronavirus Disease

Let's Google It: Assessing the Readability ADHD-Related Terms Google Searches (APA 2026) - " The first 20 Google searches were analyzed for each: "ADHD," "ADD", "attention-deficit/hyperactivity disorder," "attention deficit disorder," "Ritalin," "Concerta," and "Adderall." Texts were evaluated for word count, complex words, syllables per word, and letters per word using the Good Calculators Flesch Kincaid Calculator. ADHD-related content is significantly more difficult to read than information about ADD or medications. The lower readability of medication-related content compared to diagnostic content may prioritize pharmacological treatments over understanding ADHD or considering other interventions. This readability gap presents an opportunity to enhance accessibility and health decision-making."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting ➔ Completed

Trial completion • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Pharmacokinetics and safety study of methylphenidate hydrochloride sustained-release tablets in Chinese healthy participants. (PubMed, J Pharm Sci) - "Under both fasting and fed conditions, the test formulation demonstrated bioequivalence to the reference formulation in healthy Chinese Participants. Both preparations were safe and well-tolerated."

Journal • PK/PD data

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits (clinicaltrials.gov) - P4 | N=226 | Recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Sep 2027 ➔ May 2028 | Trial primary completion date: Sep 2027 ➔ May 2028

Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Epilepsy

BATIR: Benefits of ADHD Treatment in Detained People (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Stéphanie Baggio | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Glutamatergic Enhancement Using As-Needed Dextromethorphan and Piracetam in a Stimulant-Partially Responsive Adult With ADHD: A Single-Case Report. (PubMed, Cureus) - "Emerging evidence points to disrupted dopamine-glutamate coupling and insufficient synaptic pruning as contributors to these persistent deficits, suggesting a potential role for glutamatergic modulation inspired by ketamine's rapid neuroplastic effects. This report describes a 25-year-old man with childhood-onset ADHD who, despite trials of high-dose methylphenidate (up to 72 mg) and lisdexamfetamine (up to 80 mg), continued to report daytime lethargy, mental sluggishness, irritability, and oversleeping while on moderate-dose extended-release methylphenidate (Concerta 36-54 mg daily)...This single-case observation suggests that low-dose dextromethorphan, through brief N-methyl-D-aspartate modulation, combined with piracetam's α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) potentiation, may enhance methylphenidate's modest glutamate release, potentially promoting an AMPA-favorable plasticity state that could help mitigate pruning-related..."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Fatigue • Psychiatry

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer (clinicaltrials.gov) - P2 | N=68 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Dec 2025 ➔ Dec 2028

Trial completion date • CNS Disorders • Hematological Malignancies • Oncology • Sleep Disorder • Solid Tumor

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

New P1 trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Local Data, National Crisis: Pediatric ADHD Treatment Disruptions Amid 2024 Stimulant Shortages (AACAP 2025) - "All data used were deidentified. Of 51 total encounters, the most commonly affected medication was Vyvanse (n = 20, 39.2%), followed by Concerta (n = 14, 27.5%), Focalin XR (n = 10, 19.6%), Ritalin (n = 4, 7.8%), and Adderall (n = 3, 5.9%). These findings provide a real-time clinical snapshot of how stimulant shortages disrupted ADHD care among vulnerable pediatric populations. Even when prescriptions were ultimately filled, the process introduced delays, suboptimal substitutions, and increased burdens on families and providers. These disruptions risk exacerbating symptoms such as impulsivity, inattention, and emotional dysregulation in youth."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

The Role of Early Exposure Metrics (pAUC0-3h and Cmax,0-3h) in Assessing the Bioequivalence of Methylphenidate Extended-release Products_A Sensitivity Analysis. (PubMed, AAPS J) - "To ensure bioequivalence (BE) for products such as Concerta and Ritalin LA, both the FDA and EMA recommend the use of pAUC0-3h, with the EMA additionally suggesting the inclusion of Cmax,0-3h. Although Cmax,0-3h exhibited high sensitivity in products with dual first-order absorption, its responsiveness remained inferior to pAUC0-3h. These findings support the use of pAUC0-3h as the primary early exposure metric for therapeutic equivalence assessment and suggest that Cmax,0-3h may not provide further discriminatory value beyond that of pAUC0-3h."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Comparison between atomoxetine and OROS methylphenidate as an adjunctive to SSRIs in adult ADHD with comorbid partially responsive major depression (ECNP 2025) - "No other psychotropic drugs were permitted during the study period, except for benzodiazepines (up to 2 mg/day of lorazepam or equivalent). Our findings suggest that ATX and MPH can be used as adjunctive treatments in adults with ADHD and comorbid partially responsive MDD. The efficacy and tolerability of ATX and MPH in adults with ADHD did not differ significantly. Further well-designed studies should be conducted to draw a definitive conclusion and to better understand the relationship between ADHD and depressive disorders."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • General Anxiety Disorder • Major Depressive Disorder • Mood Disorders • Psychiatry

Challenges in the Treatment of Narcolepsy and the Positive Impact of Acetyl-L-Carnitine: A Case-Based Review with 20-Year Follow-Up (WSS 2025) - "Initial pharmacologic management included antidepressants, Modafinil, Armodafinil, Adderall, Concerta, Jornay, Vyvanse, and sodium oxybate (Xyrem). This case highlights the multifaceted challenges in narcolepsy management and proposes acetyl-L-carnitine as a potential adjuvant therapy in refractory cases. Given its safety profile and observed benefit in this case, ALCAR warrants further investigation through controlled clinical trials."

Clinical • Review • Barrett Esophagus • Cataplexy • CNS Disorders • Excessive Daytime Sleepiness • Gastrointestinal Disorder • Mental Retardation • Metabolic Disorders • Mood Disorders • Narcolepsy • Psychiatry • Sleep Disorder

Treatment Considerations in Co-morbid Schizophrenia and Narcolepsy: A Case Report (WSS 2025) - "Some alertness promoting medications used in narcolepsy treatment, such as modafinil, methylphenidate and amphetamine, may exacerbate psychosis by increasing dopamine activity...He was previously intolerant to modafinil (emotional numbing) and Concerta (appetite suppression) as per chart review.Paliperidone was effective for psychosis but worsened sleepiness, which was disabling... In conclusion, some traditional stimulants may worsen psychosis in PWN. Pitolisant, an inverse H3 agonist, which does not theoretically affect dopamine pathways, may be a suitable treatment for sleepiness and cataplexy in comorbid psychosis."

Case report • Clinical • Cataplexy • CNS Disorders • Narcolepsy • Psychiatry • Schizophrenia • Sleep Disorder

Pharmacokinetics and Bioequivalence of a Novel Extended-Release Formulation of Methylphenidate Hydrochloride for Attention-Deficit/Hyperactivity Disorder. (PubMed, Clin Pharmacol Drug Dev) - "In the first trial (N = 60), a single 72-mg tablet of ODX-methylphenidate ER was compared to two 36-mg tablets of OROS-methylphenidate ER, while in the second trial (N = 36), a single 54-mg tablet of ODX-methylphenidate ER was compared to a 54-mg tablet of OROS-methylphenidate ER. Statistical bioequivalence between the 2 formulations was confirmed for maximum drug concentration, area under the concentration-time curve from time 0 to 3 hours after dosing (AUC0-3 h), AUC from 3 to 7 hours after dosing, AUC from 7 to 12 hours after dosing, and AUC from time 0 extrapolated to infinity in both trials. Safety and tolerability were similar for both products and in both trials, with no serious adverse events reported."

Journal • PK/PD data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Drugs for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Structural basis for Salmonella infection by two Microviridae phages. (PubMed, Commun Biol) - "Here, we identify two Microviridae phages, PJNS001 and PJNS002, with different host receptor dependencies, and determine their cryo-EM structures at 2.68 Å and 2.59 Å resolution, respectively...Structural analysis and in situ visualization reveal spike protein features and host-attachment intermediates, informing host specificity. Together, these findings advance our understanding of Microviridae infection mechanisms and provide a structural framework for rational phage design against antibiotic-resistant pathogens."

Journal • Infectious Disease

"The disruptive effects of methylphenidate treatment on circadian rhythm in adult female zebrafish and epigenetic transmission of its negative effects to offspring.". (PubMed, Physiol Behav) - "Numerous medications have been developed to manage ADHD, with methylphenidate (commonly known as Ritalin or Concerta) being the most widely used active compound. In the offspring of the next generation, it was observed that the telomere length inherited at birth was shorter when treated with MPH only. Also, methylation in the FOXM1 is observed in MPH-only treatment group, and compensated with combinational treatments for melatonin and oxytocin."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Inflammation • Mood Disorders • Psychiatry • Sleep Disorder • FOXM1

Complex ADHD in a Child With Tic Disorder. (PubMed, J Dev Behav Pediatr) - "He is currently prescribed OROS methylphenidate 54 mg capsules once daily in the morning, which he has taken for 3 years. There was no accompanying vocalization with this movement.His parents are requesting a medication adjustment or change. What would you do?"

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Cognitive Disorders • Mood Disorders • Movement Disorders • Psychiatry • Tic Disorders • Tourette Syndrome

CHEC2023-296: Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. (clinicaltrials.gov) - P=N/A | N=210 | Recruiting | Sponsor: Lei Lei, MD | Trial completion date: Aug 2025 ➔ Dec 2025 | Trial primary completion date: Aug 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Rabbit Syndrome: A Rare Iatrogenic Tremor Due to Discontinuation of Aripiprazole (APA 2025) - "Patient was initially managed with Effexor and Buspar for anxiety before switching to Lexapro and Abilify in 2020...Patient's Abilify was initially reduced to 5mg daily, Requip 1mg nightly for RLS and Concerta 54mg daily for ADHD...Management includes tapering off antipsychotics, switching medications, or using anticholinergics like Benztropine or Trihexiphenidyl. ß-blockers may also provide relief. Further research is necessary to better understand and treat Rabbit syndrome."

Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Infectious Disease • Mood Disorders • Movement Disorders • Psychiatry • DRD2

Methylphenidate for Ptsd and Stroke Veterans (clinicaltrials.gov) - P1/2 | N=20 | Completed | Sponsor: VA Office of Research and Development | Recruiting ➔ Completed | Phase classification: P2 ➔ P1/2 | N=60 ➔ 20 | Trial completion date: Sep 2026 ➔ May 2025 | Trial primary completion date: Sep 2026 ➔ May 2025

Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder